Présentation de l'entreprise
Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical entity dedicated to the discovery, development, and commercialization of pharmaceutical products designed for the treatment of human diseases, with a specific focus on sotagliflozin, an orally delivered small molecule drug targeting hypertrophic cardiomyopathy. The company functions within the Healthcare sector and the Biotechnology industry, a classification that signifies its reliance on intensive research and development cycles and regulatory approval processes rather than traditional manufacturing economies of scale. As of the latest reporting period, the organization employs a workforce of 81 individuals and holds a market capitalization of $707.55M. With an annual revenue of $49.80M, these valuation and revenue figures indicate that Lexicon occupies a niche position within the broader biotechnology landscape, characterized by a market cap that is substantial relative to its revenue base but typical for pre-commercialization or late-stage development biotech firms that prioritize asset value over immediate profitability.
Santé financière
The company reported a revenue of $49.80M over the trailing twelve months, while posting a net income of $-50,341,000 and an EBITDA of $-48,290,000. The significant divergence between the $49.80M in revenue and the -$50.34M in net income reveals a highly expansive cost structure where operating expenses, likely driven by research, development, and clinical trial costs, exceed total revenue generation. Free cash flow stands at $-47,815,248, indicating that the company is consuming cash reserves to fund its operations and growth initiatives, which limits immediate financial flexibility and necessitates ongoing capital access. The gross margin is calculated at 86.8%, reflecting the high cost-efficiency of producing pharmaceutical products once developed, whereas the operating margin of -269.1% and profit margin of -101.1% demonstrate that overhead and R&D expenditures are severely eroding operating profitability. On the balance sheet, the company holds $96.23M in cash against $62.24M in debt, resulting in a debt-to-equity ratio of 57.87. This leverage position suggests a moderately leveraged balance sheet where the company carries significant obligations relative to its equity base, yet retains sufficient cash liquidity to cover current liabilities given a current ratio of 4.88. Return on Equity is recorded at -39.7% and Return on Assets at -12.6%, metrics that collectively reveal that management is currently unable to generate positive returns on the capital invested in the company, consistent with the financial profile of a company in a heavy investment phase.
Évaluation de la valorisation
Valuation metrics for Lexicon Pharmaceuticals, Inc. present a complex picture, with a trailing P/E ratio listed as N/A and a forward P/E of -8.03. The absence of a trailing P/E and the negative forward P/E imply that the company is not yet profitable and that future earnings projections are insufficient to cover current share prices, a common characteristic of biotech firms awaiting commercial milestones. The price-to-book ratio stands at 5.64, indicating that the market values the company at a significant premium over its net asset value, which often reflects the potential value of its intellectual property and pipeline assets rather than current book equity. Alternative valuation measures such as a price-to-sales ratio of 14.21 and an EV/EBITDA of -13.95 further underscore that the stock is priced based on future revenue potential rather than current earnings power. Regarding trading ranges, the 52-week high is $1.83 and the 52-week low is $0.45, meaning the current share price sits below the annual high and reflects the volatility inherent in small-cap biotechnology stocks. The beta value of 0.95 indicates that the stock's price volatility is roughly in line with the broader market, suggesting it does not exhibit extreme sensitivity to general market movements despite its specific sector risks.
Growth & Income
Lexicon Pharmaceuticals, Inc. experienced a revenue growth rate of -79.3% year-over-year, while earnings growth is listed as N/A due to the lack of profitability. The negative revenue growth signifies a contraction in sales or a shift in the revenue recognition model, likely associated with the timing of product launches or commercialization phases, rather than a decline in underlying product value. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all available earnings and cash flow back into research, development, and commercialization efforts rather than distributing income to shareholders. This non-dividend profile is typical for biotechnology companies that must preserve capital to sustain operations and achieve regulatory approval for their pharmaceutical products. Overall, the growth and income profile of Lexicon Pharmaceuticals is defined by significant revenue contraction and a complete absence of current earnings or dividend distributions, positioning the company as a high-risk, high-potential asset dependent on future commercial success.